Gsk pharma stock price: The day of February 17 proved to be extremely good for the shares of Glaxosmithkline Pharma i.e. GSK Pharma. Due to increase in procurement, the price on BSE climbed up to 20 percent from the last closed price in the day to hit the upper circuit of Rs 2,421.30. The company’s market cap has been Rs 40200 crore. After the company’s good October-December 2024 quarterly results, Brokerage, such as ICICI Securities and Motilal Oswal, has retained positive ratings for stock.
In the December 2024 quarter, GSK Pharma’s net profit increased by more than 5 times on an annual basis to Rs 229 crore. A year ago, the profit was Rs 45 crore. Consolidated revenue from operations increased to Rs 949 crore, which was Rs 805 crore in the December 2023 quarter. Ebitda increased by 29.8 percent to Rs 2.8 billion on an annual basis and Ebitda margin 270 basis points increased to 29.7 percent.
Brokerage gave the rating and target price for GSK Pharma
After the quarterly results, ICICI Securities have increased the estimates of GSK Pharma’s financial year FY25–26e to about 5 to 6 percent for income for income. This is mainly caused by better margin outlook. Brokerage has reduced the target price for the stock to Rs 2,250 per share and has increased the rating to ‘ed’. Meanwhile, Motilal Oswal has also increased the earning estimate of FY25/FY26/FY27 for GSK Pharma by 2 percent/5 percent/7 percent. The target price is kept at Rs 2,170 per share.
Promoters have 75 percent stake
GSK Pharma had a 75 percent stake in GSK Pharma till the end of December 2024. The stock has seen only 4 percent strength in a year. The stock has a 52 -week high level of Rs 3,087.95 on BSE and a 52 -week low of Rs 1,825.05.